Literature DB >> 16127089

Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus.

Mandy Wootton, T R Walsh, A P MacGowan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16127089      PMCID： PMC1195430          DOI： 10.1128/AAC.49.9.3982-3983.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  13 in total

1.  Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin.

Authors:  P B Ward; P D Johnson; E A Grabsch; B C Mayall; M L Grayson
Journal:  Med J Aust       Date:  2001-11-05       Impact factor: 7.738

Review 2.  Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections.

Authors:  P A Moise; J J Schentag
Journal:  Int J Antimicrob Agents       Date:  2000-11       Impact factor: 5.283

3.  Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.

Authors:  J Ariza; M Pujol; J Cabo; C Peña; N Fernández; J Liñares; J Ayats; F Gudiol
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

4.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

Authors:  M Wootton; R A Howe; R Hillman; T R Walsh; P M Bennett; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

5.  Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.

Authors:  T R Walsh; A Bolmström; A Qwärnström; P Ho; M Wootton; R A Howe; A P MacGowan; D Diekema
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

6.  Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization.

Authors:  Soraya Andrade-Baiocchi; Maria Cristina B Tognim; Otavio C G Baiocchi; Helio S Sader
Journal:  Diagn Microbiol Infect Dis       Date:  2003-02       Impact factor: 2.803

7.  Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.

Authors:  Patrick G P Charles; Peter B Ward; Paul D R Johnson; Benjamin P Howden; M Lindsay Grayson
Journal:  Clin Infect Dis       Date:  2004-01-12       Impact factor: 9.079

8.  Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.

Authors:  Christopher W Woods; Allen C Cheng; Vance G Fowler; Mary Moorefield; Joyce Frederick; George Sakoulas; Venkata G Meka; Fred C Tenover; Peter Zwadyk; Kenneth H Wilson
Journal:  Clin Infect Dis       Date:  2004-04-05       Impact factor: 9.079

9.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

Authors:  Scott K Fridkin; Jeff Hageman; Linda K McDougal; Jasmine Mohammed; William R Jarvis; Trish M Perl; Fred C Tenover
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079
View more
  10 in total

1.  Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.

Authors:  Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Kathy Smith; Cynthia D Todd; Amanda Wehler; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

2.  Vancomycin dosage regimens for pediatric patients.

Authors:  Milap C Nahata
Journal:  J Pediatr Pharmacol Ther       Date:  2009-04

3.  Correlation of vancomycin dosing to serum concentrations in pediatric patients: a retrospective database review.

Authors:  Kim W Benner; Mary A Worthington; David W Kimberlin; Kim Hill; Kevin Buckley; Nancy M Tofil
Journal:  J Pediatr Pharmacol Ther       Date:  2009-04

4.  Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.

Authors:  Pierre Vaudaux; Elzbieta Huggler; Louis Bernard; Tristan Ferry; Adriana Renzoni; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

5.  Penetration of daptomycin into bone and synovial fluid in joint replacement.

Authors:  D Montange; F Berthier; G Leclerc; A Serre; L Jeunet; M Berard; P Muret; L Vettoretti; J Leroy; B Hoen; C Chirouze
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

6.  High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus.

Authors:  Ilker Uçkay; Louis Bernard; Marta Buzzi; Stephan Harbarth; Patrice François; Elzbieta Huggler; Tristan Ferry; Jacques Schrenzel; Adriana Renzoni; Pierre Vaudaux; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

7.  Hetero-vancomycin-intermediate methicillin-resistant Staphylococcus aureus isolate from a medical center in Las Cruces, New Mexico.

Authors:  Alejandro Delgado; James T Riordan; Reena Lamichhane-Khadka; David C Winnett; Jennifer Jimenez; Kim Robinson; Frances G O'Brien; Stephanie A Cantore; John E Gustafson
Journal:  J Clin Microbiol       Date:  2007-01-31       Impact factor: 5.948

8.  Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.

Authors:  Anne Yusof; Anette Engelhardt; Asa Karlsson; Lina Bylund; Pamela Vidh; Karen Mills; Mandy Wootton; Timothy R Walsh
Journal:  J Clin Microbiol       Date:  2008-07-02       Impact factor: 5.948

9.  Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.

Authors:  Wenjia Sun; Hongbin Chen; Yudong Liu; Chunjiang Zhao; Wright W Nichols; Minjun Chen; Jianzhong Zhang; Yue Ma; Hui Wang
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

10.  Accessory Gene Regulator Polymorphism and Vancomycin Minimum Inhibitory Concentration in Methicillin-Resistant Staphylococcus aureus.

Authors:  Min-Jeong Park; Han-Sung Kim; Hyun Soo Kim; Jae-Seok Kim; Wonkeun Song; Mi Young Kim; Young Kyung Lee; Hee Jung Kang
Journal:  Ann Lab Med       Date:  2015-05-21       Impact factor: 3.464
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.